545 Neoantigen-loaded dendritic cell vaccine for cancer prevention in lynch syndrome: early results from a phase Ib clinical trial
Year: 2026
Type: conference-abstract
Abstract: Background Lynch syndrome (LS), caused by germline pathogenic variants in DNA mismatch repair (MMR) genes, confers increased lifetime risk of colorectal and endometrial cancers, among other malignancies. While colorectal cancer surveillance is effective, preventive approaches for most other LS-associated tumours are lacking. Dendritic cell (DC)–based cancer vaccines show immunogenicity in therapeutic settings, but their greatest potential may lie in cancer prevention in high-risk populations. We initiated a first-in-human phase Ib clinical trial (DELAY, NCT07163403) evaluating an autologous DC vaccine loaded with 24 previously identified LS-associated HLA-I and II-restricted neoepitopes1 separated in 4 pools for cancer prevention in LS carriers. The primary objectives are to assess safety and the induction of neoantigen-specific immune responses.Methods To date, 10 cancer-free LS individuals without oncological history have been enrolled. The DELAY product was administered as six doses of 10 million DCs per dose at two-week intervals. Peripheral-blood mononuclear cells (PBMCs) were collected at baseline, mid and end of treatment, and 6 months after treatment. PBMCs were pre-expanded for 2 weeks with the neoantigen peptide pools and evaluated for immunogenicity using IFN-γ ELISPOTs and flow cytometry assessment of activation-induced markers (AIM). Pre-and post-vaccination colonic biopsies are obtained to assess tissue-level immune responses. When detected, neoantigen-specific T-cells were isolated by FACS through AIM. TCR repertoire analysis and paired single-cell RNA/TCR sequencing were performed in selected baseline and post-vaccination PBMC samples and baseline colonic tissue.Results The vaccine was well-tolerated without grade 3 or 4 adverse events. After vaccination, 5 out of 5 analysed individuals responded to ≥2 peptide pools (1–2 peptides/pool), as defined by IFN-γ ELISPOT responses and AIM markers after in vitro restimulation. Antigen-specific responses were sustained for at least 6 months (n = 2) (figure 1). TCR repertoire analysis confirmed the expansion of >39 clonotypes above a 0.3% threshold at the end of treatment for n = 2 patients (figure 2). By tracking neoantigen-reactive clonotypes in paired single cell RNA and TCR sequencing data we reveal that expanding clonotypes adopt non-exhausted effector states. Moreover, we validated the functional relevance of isolated neoantigen-specific CD8+ T-cell with effector phenotype by showing antigen-specific killing of neoantigen-expressing HLA-matched K562 target cells, suggesting their relevance for cancer prevention.Conclusions To date, vaccination with the DELAY product is safe and induces functional cellular immune responses against multiple LS-associated neoantigens. This work was supported by ISCIII grants PICI and FIS(ICI22/00063,PI22/00470), AECC (P-PI049999-AEGEN).Reference Bayó C, Castellano G, et al. Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies. J Immunother Cancer. 2025;13(4):e011177.Ethics Approval This study was approved by IDIBAPs institution’s Ethics Board; approval number HCB/2024/0648. Participants have read and signed informed consent before enrolling into the clinical trial.Abstract 545 Figure 1Trial design and immunogenicity of a neoantigen-loaded dendritic cell vaccine in Lynch syndrome. (A) Schematic overview of the clinical trial design; (B) Heatmap depicting IFNγ ELISPOT responses; (C) Peptide specificity corroboration and target cytotoxicityAbstract 545 Figure 2Erichment test of TRB CDR3aa sequences across treatment timepoints. (A) Fraction of reads from expanded clonotypes shared across all timepoints; (B) Bubbleplot-heatmap depicting Log2FoldChange (FC) from expanded clonotypes shared across timepoints
Authors: Cristina Bayó, Joaquin Castillo, Alejandro Ramírez-Chacón, Andrea Aran, Georgina Flórez-Grau, Maria Chacon, Liseth Rivero, Maria Daca, Maria Pellisé, Leticia Moreira, Teresa Ocaña, Sergio Navarro, Miquel Lozano, Sabela Carballal, Hardeep Kumari, Manel Juan, Thomas Walle, Daniel Benitez, Francesc Balaguer
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225309563
